Immunogen, inc. (IMGN)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues:
License and milestone fees

-

-

-

-

-

-

-

-

-

-

-

54,962

-

-

20,921

26,915

31,925

26,926

57,651

57,815

53,034

48,261

32,522

39,455

40,005

61,710

36,461

24,227

24,322

3,311

8,907

9,161

11,070

10,929

5,770

6,393

0

0

0

Royalty revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

13,867

17,290

14,749

12,459

10,346

7,538

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Non-cash royalty revenue related to the sale of future royalties

-

-

-

-

-

-

-

-

-

-

-

26,946

-

-

25,799

25,299

24,839

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development support

-

-

-

-

-

-

-

-

-

-

-

5,161

-

-

4,596

4,014

3,387

2,860

2,844

2,848

3,467

4,883

5,973

7,187

8,063

8,372

8,486

7,873

6,854

5,917

4,826

4,517

4,899

5,769

6,829

7,256

0

0

0

Clinical materials revenue

-

-

-

-

-

-

-

-

-

-

-

1,956

-

-

1,300

3,579

4,882

4,402

5,825

5,527

4,882

6,228

4,927

2,908

2,378

1,048

1,070

2,843

3,480

3,679

4,179

2,679

3,941

5,171

5,831

5,656

0

0

0

Total revenues

86,974

82,271

50,823

48,470

42,215

53,446

79,478

77,030

106,763

115,447

89,845

89,025

57,413

48,628

52,811

60,002

65,205

56,918

87,189

85,541

78,673

74,121

55,881

59,896

57,984

76,110

48,662

35,535

34,656

12,907

17,912

16,357

19,910

21,869

18,430

19,305

0

0

0

Operating expenses:
Research and development

103,037

114,522

132,148

158,376

168,518

174,456

170,618

155,064

151,682

139,739

133,553

134,773

138,106

141,312

145,854

148,077

139,862

129,434

118,882

111,768

107,118

119,732

112,947

106,958

101,570

84,608

85,402

87,073

86,213

81,828

75,731

69,192

67,914

66,744

67,189

63,453

0

0

0

General and administrative

36,575

38,489

38,438

37,577

37,529

36,746

36,042

35,603

35,787

33,911

33,399

34,950

35,412

38,528

38,046

36,916

34,879

30,644

29,462

28,228

27,423

26,463

25,038

24,469

23,386

22,341

22,358

21,471

21,824

21,850

21,220

20,422

19,134

18,663

17,517

16,040

0

0

0

Restructuring charge

21,699

21,433

21,327

21,177

2,521

3,693

3,680

2,810

2,124

779

687

4,817

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

161,311

174,444

191,913

217,130

208,568

214,895

210,340

193,477

189,593

174,429

167,639

174,540

178,335

184,271

188,030

184,993

174,741

160,078

148,344

139,996

134,541

146,195

137,985

131,427

124,956

106,949

107,760

108,544

108,037

103,678

96,951

89,614

87,048

85,407

84,706

79,493

0

0

0

Loss from operations

-74,337

-92,173

-141,090

-168,660

-166,353

-161,449

-130,862

-116,447

-82,830

-58,982

-77,794

-85,515

-120,922

-135,643

-135,219

-124,991

-109,536

-103,160

-61,155

-54,455

-55,868

-72,074

-82,104

-71,531

-66,972

-30,839

-59,098

-73,009

-73,381

-90,771

-79,039

-73,257

-67,138

-63,538

-66,276

-60,188

0

0

0

Investment income, net

3,648

4,424

5,123

5,460

0

-

-

-

-

-

-

517

-

473

420

325

252

158

112

69

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes

19,149

16,879

13,953

12,224

11,017

10,631

11,424

12,263

13,153

13,682

14,108

15,741

17,196

18,593

20,005

20,130

20,611

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense on convertible senior notes

95

95

96

95

95

95

98

837

1,939

3,040

4,111

4,499

3,512

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash debt conversion expense

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

463

590

-730

-284

0

-

-

-

-

-

-

143

-

-583

284

117

526

-418

-574

-916

-976

-590

-368

123

106

74

127

72

-35

37

-55

-128

83

149

1,407

1,914

0

0

0

Net loss

-89,470

-104,133

-150,746

-175,803

-173,981

-168,843

-140,162

-150,037

-117,280

-96,012

-117,046

-105,095

-142,150

-156,733

-155,808

-144,817

-129,369

-119,059

-72,197

-60,739

-56,764

-72,598

-82,420

-71,364

-66,740

-30,639

-58,845

-72,811

-73,350

-90,668

-79,028

-73,319

-67,055

-63,389

-64,869

-58,274

0

0

0

Loss before benefit for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-58,274

0

0

0

Basic and diluted net loss per common share (in dollar per share)

-0.17

0.03

-0.15

-0.29

-0.30

-0.28

-0.32

-0.31

-0.30

-0.11

-0.61

-0.10

-0.20

-0.39

-0.51

-0.53

-0.37

-0.38

-0.39

-0.35

-0.25

0.16

-0.26

-0.31

-0.44

0.04

-0.13

-0.26

-0.02

-0.29

-0.30

-0.29

-0.24

-0.17

-0.26

-0.23

-0.22

-0.21

-0.19

Basic and diluted weighted average common shares outstanding (in shares)

166,947

148,823

148,479

148,129

147,813

-

-

-

-

-

-

87,174

-

87,214

86,990

87,062

87,035

-

86,838

-

-

-

85,872

-

85,684

-

85,010

-

84,279

-

83,350

77,408

76,961

76,523

76,364

-

-

-

-

Basic weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86,080

85,935

-

-

-

85,431

-

-

-

84,147

-

-

-

-

-

-

-

-

-

Dilutive impact of potential common shares (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

730

-

-

-

1,845

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted weighted average common shares outstanding (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

86,665

-

-

-

87,276

-

-

-

84,147

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-89,470

-104,133

-150,746

-175,803

0

-

-

-

-

-

-

-105,095

-

-156,733

0

0

0

-

-72,197

-60,739

-56,764

-72,598

-82,420

-71,364

-66,740

-30,639

-58,845

-72,811

-73,350

-90,668

-79,028

-73,319

0

0

0

-

-

-

-

License and milestone fees
Total revenues

34,992

34,788

6,984

7,577

3,819

15,280

43,113

42,520

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash royalty revenue related to the sale of future royalties
Total revenues

51,924

47,415

41,383

36,622

33,452

32,154

30,460

28,522

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development support
Total revenues

58

68

286

674

1,011

1,377

1,611

1,873

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Clinical materials revenue
Total revenues

-

-

-

-

-

4,635

4,294

4,115

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-